Stock price when the opinion was issued
Global leader in hip and knee replacement, also wound management. Great secular growth story. Earnings weak last couple of years. Demographic and pickleball play. Lowest valuation in 50 years, 14x PE, 12x next year's PE. Revenues re-accelerating. Earnings and margins growing. Yield is 3.7%.
Cheaper than SYK, and probably more narrowly focused.
It is a UK medical tool company. It is a reasonable company but you have to buy it when it works and when it's on sale. There are better opportunities.